Baidu
map

新进展!国际研究团队发现"渐冻症"治疗新靶点

2022-07-06 新华社 网络

在28个靶点中,有18个靶点可减缓神经退行性症状。

随着深度学习等技术进步,人工智能在新药研发中扮演着越发重要的角色。近日,中国学者参与的国际研究团队利用人工智能发现了“渐冻症”的潜在治疗靶点,为该疾病的治疗提供了新思路。

“渐冻症”医学名称为肌萎缩侧索硬化症,是一种神经退行性疾病,会影响大脑和脊髓中的运动神经元,造成运动神经元死亡,令大脑无法控制肌肉运动。主要临床表现是肌肉逐渐萎缩无力,患者最后会因呼吸衰竭而死亡。目前“渐冻症”的治疗原则以减轻症状为主,已获批用于治疗“渐冻症”的药物几乎不能逆转患者的任何神经退行性症状。

在人工智能药物研发公司英矽智能、美国约翰斯·霍普金斯大学医学院、哈佛大学附属马萨诸塞综合医院、中国清华大学等机构合作的研究中,研究人员利用名为“PandaOmics”的人工智能生物靶点发现平台分析了来自多个公共数据集的大量中枢神经系统样本转录组数据,以及大量“渐冻症”患者运动神经元样本的转录组和蛋白组数据。

人工智能通过分析这些与“渐冻症”疾病进展有关的大数据,从中确定了17个高置信度靶点和11个全新治疗靶点。研究人员随后在模拟“渐冻症”患者情况的果蝇模型中进行验证,证实在上述28个靶点中,有18个靶点可减缓神经退行性症状。

相关论文已于近日发表在国际期刊《衰老神经科学前沿》杂志上。论文作者之一、清华大学药学院教授鲁白接受新华社记者采访时表示:“从由人工智能驱动在海量数据集中发现靶点,到在小鼠、果蝇等多个模型系统中进行生物验证,再到通过研究者发起的试验进行快速临床测试,这代表了一种新趋势,有望大大降低药物开发的成本和时间。更重要的是成功率的提升,特别是针对神经退行性疾病而言。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1269713, encodeId=c3781269e136a, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288347, encodeId=e6fd128834e37, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517400, encodeId=9c3c151e400ff, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570066, encodeId=686415e00662b, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230913, encodeId=cf601230913ea, content=再次显示人口多的好处。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Jul 06 14:16:10 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-07 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1269713, encodeId=c3781269e136a, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288347, encodeId=e6fd128834e37, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517400, encodeId=9c3c151e400ff, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570066, encodeId=686415e00662b, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230913, encodeId=cf601230913ea, content=再次显示人口多的好处。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Jul 06 14:16:10 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-07 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1269713, encodeId=c3781269e136a, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288347, encodeId=e6fd128834e37, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517400, encodeId=9c3c151e400ff, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570066, encodeId=686415e00662b, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230913, encodeId=cf601230913ea, content=再次显示人口多的好处。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Jul 06 14:16:10 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1269713, encodeId=c3781269e136a, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288347, encodeId=e6fd128834e37, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517400, encodeId=9c3c151e400ff, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570066, encodeId=686415e00662b, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230913, encodeId=cf601230913ea, content=再次显示人口多的好处。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Jul 06 14:16:10 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1269713, encodeId=c3781269e136a, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288347, encodeId=e6fd128834e37, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517400, encodeId=9c3c151e400ff, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570066, encodeId=686415e00662b, content=<a href='/topic/show?id=f60de338081' target=_blank style='color:#2F92EE;'>#研究团队#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73380, encryptionId=f60de338081, topicName=研究团队)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15c315623764, createdName=changhe718, createdTime=Thu Jul 07 06:30:11 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230913, encodeId=cf601230913ea, content=再次显示人口多的好处。, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Wed Jul 06 14:16:10 CST 2022, time=2022-07-06, status=1, ipAttribution=)]
    2022-07-06 weigq

    再次显示人口多的好处。

    0

相关资讯

Nat Med:反义寡核苷酸沉默FUS表达可治疗肌萎缩侧索硬化症

在小鼠遗传和人类临床研究中,研究人员提供了支持FUS沉默作为FUS依赖性ALS和FTD治疗策略的证据。

JNNP:基于患者偏好的肌萎缩侧索硬化临床试验终点研究

肌萎缩侧索硬化 (ALS) 患者的延髓、手臂、腿部和/或呼吸功能受到多个方面的影响。 修订后的 ALS 功能评定量表 (ALSFRS-R) 是评估这些领域最常用的方法。 其总分已成为 AL

JNNP:C9orf72相关额颞叶痴呆和肌萎缩侧索硬化症的脑脊液生物标记物分析方法的开发

C9orf72第一内含子的GGCC重复序列扩增是肌萎缩侧索硬化症(ALS)和额颞痴呆症(FTD)最常见的遗传原因,分别占家族病例的38%和25%。健康人通常有两个重复,而C9FTD/ALS(C9FTD

JNNP:伴TARDBP突变的肌萎缩侧索硬化症患者的18-氟脱氧葡萄糖正电子发射断层扫描结果改变

肌萎缩侧索硬化症(ALS)是一种运动神经元变性疾病,在发病后2-5年内导致死亡。

Muscle Nerve:间充质干细胞治疗ALS的3期临床试验失败

肌萎缩侧索硬化(ALS)是一种神经退行性疾病,其特征是皮质和脊髓运动神经元的进行性变性和丢失。神经炎症起着重要作用。目前还没有治愈ALS的方法,也没有任何治疗方法可以阻止或逆转疾病的进展。以多种疾病途

Baidu
map
Baidu
map
Baidu
map